OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.
More OpGen content >Investment summary
OpGen is a diagnostic company focused on revolutionizing the identification and treatment of bacterial infections. With the recent 510(k) clearance of the Acuitas AMR Gene Panel in bacterial isolates, OpGen has reached the next stage of its corporate evolution. As a reminder, the panel detects 28 genetic antimicrobial resistance (AMR) markers in isolated bacterial colonies from 26 different pathogens and provides genomic profile data much quicker than traditional methods (2.5 hours versus one to four days).
Y/E Dec |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2019A | 3.5 | (11.7) | (11.9) | (737.57) | N/A | N/A |
| 2020A | 4.2 | (22.0) | (25.3) | (157.41) | N/A | N/A |
| 2021E | 3.8 | (26.2) | (30.9) | (85.48) | N/A | N/A |
| 2022E | 8.3 | (23.2) | (25.5) | (0.63) | N/A | N/A |
Industry outlook
It currently takes days to test a patient sample to find out if they have an infection, what they are infected with and to which drugs that infection might be susceptible. This can lead to a delay in treatment or the wrong treatment being prescribed. According to the Centers for Disease Control and Prevention, there are over two million cases of drug-resistant bacterial infections every year.
Last updated on 18/01/2022Content on OpGen
Sector |
|---|
|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (US$m) | 7.2 |
| Forecast gearing ratio (%) | 30 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Oliver Schacht | CEO |
You may also be interested in…
- Abacus Health Products
- Aditxt
- Atossa Genetics
- Auris Medical Holding
- Australis Capital
- Bioasis Technologies
- BioLargo
- CASI Pharmaceuticals
- Cellular Biomedicine Group
- Hepion Pharmaceuticals
- InMed Pharmaceuticals
- International Stem Cell
- Jaguar Health
- Orexigen Therapeutics
- PDL BioPharma
- SIGA Technologies
- Sunesis Pharmaceuticals